A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer.
CONCLUSIONS: The combination of cetuximab, gemcitabine, and radiation resulted in significant toxicity. A recommended phase II dose could not be determined.
PMID: 23077684 [PubMed]
Source: Gastrointestinal Cancer Research - Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research
More News: Adenocarcinoma | Allergy & Immunology | Cancer | Cancer & Oncology | Erbitux | Gastroenterology | Liver | Pancreas | Pancreatic Cancer | Stroke | Study | Toxicology | Urology & Nephrology